Download PDF
Dtsch Med Wochenschr 2009; 134(39): 1949-1952
DOI: 10.1055/s-0029-1237538
Prinzip & Perspektive | Review article
Hämatologie
© Georg Thieme Verlag KG Stuttgart · New York

Systemische Leichtketten-Amyloidose – Molekulare Grundlagen und klinische Perspektiven

Systemic lightchain amyloidosis – molecular basis and clinical perspectivesS. O. Schönland1 , M. Moos1 , T. Bochtler1 , A. D. Ho1 , U. Hegenbart1
  • 1Abteilung Innere Medizin V (Hämatologie, Onkologie und Rheumatologie), Medizinische Klinik, Universitätsklinikum Heidelberg
Further Information

Publication History

eingereicht: 30.4.2009

akzeptiert: 12.7.2009

Publication Date:
16 September 2009 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Proteinfehlfaltung - AL-Amyloidose - monoklonale Gammopathie - chromosomale Instabilität

Keywords

protein misfolding - AL amyloidosis - monoclonal gammopathy - chromosomal instability

Literatur

  • 1 Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis – the archetype of structural and pathogenic variability.  J Struct Biol. 2000;  130 280-289
    Search in Google Scholar
  • 2 Bochtler T, Hegenbart U, Cremer F W, Heiss C, Benner A, Hose D, Moos M, Bila J, Bartram C R, Ho A D, Goldschmidt H, Jauch A, Schonland S O. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.  Blood. 2008;  111 4700-4705
    Search in Google Scholar
  • 3 Bochtler T, Hegenbart U, Heiss C, Benner A, Cremer F, Volkmann M, Ludwig J, Perz J B, Ho A D, Goldschmidt H, Schonland S O. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.  Haematologica. 2008;  93 459-462
    Search in Google Scholar
  • 4 Comenzo R L, Zhang Y, Martinez C, Osman K, Herrera G A. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.  Blood. 2001;  98 714-720
    Search in Google Scholar
  • 5 Dispenzieri A, Lacy M Q, Zeldenrust S R, Hayman S R, Kumar S K, Geyer S M, Lust J A, Allred J B, Witzig T E, Rajkumar S V, Greipp P R, Russell S J, Kabat B, Gertz M A. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.  Blood. 2007;  109 465-470
    Search in Google Scholar
  • 6 Ehrnhoefer D E, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker E E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.  Nat Struct Mol Biol. 2008;  15 558-566
    Search in Google Scholar
  • 7 Falk R H, Comenzo R L, Skinner M. The systemic amyloidoses.  N Engl J Med. 1997;  337 898-909
    Search in Google Scholar
  • 8 Kaplan B, Livneh A, Gallo G. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease.  Br J Haematol. 2007;  136 723-728
    Search in Google Scholar
  • 9 Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos M A. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.  Haematologica. 2007;  92 1351-1358
    Search in Google Scholar
  • 10 Mereles D, Wanker E E, Katus H A. Therapy effects of green tea in a patient with systemic light-chain amyloidosis.  Clin Res Cardiol. 2008;  97 341-344
    Search in Google Scholar
  • 11 Merlini G, Bellotti V. Molecular mechanisms of amyloidosis.  N Engl J Med. 2003;  349 583-596
    Search in Google Scholar
  • 12 Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.  Blood. 2004;  103 2936-2938
    Search in Google Scholar
  • 13 Reece D E. Recent trends in the management of newly diagnosed multiple myeloma.  Curr Opin Hematol. 2009;  16 306-312
    Search in Google Scholar
  • 14 Reece D E, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand J P, Vescio R A, Liu X, Elsayed Y A, Cakana A, Comenzo R L. Weekly and twice-weekly bortezomib in patients with systemic AL-amyloidosis: results of a phase 1 dose-escalation study.  Blood. 2009, Jun 4. [Epub ahead of print]; 
    Search in Google Scholar
  • 15 Rocken C, Sletten K. Amyloid in surgical pathology.  Virchows Arch. 2003;  443 3-16
    Search in Google Scholar
  • 16 Ronchetti D, Finelli P, Richelda R, Baldini L, Rocchi M, Viggiano L, Cuneo A, Bogni S, Fabris S, Lombardi L, Maiolo A T, Neri A. Molecular analysis of 11q13 breakpoints in multiple myeloma.  Blood. 1999;  93 1330-1337
    Search in Google Scholar
  • 17 Sanchorawala V, Skinner M, Quillen K, Finn K T, Doros G, Seldin D C. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.  Blood. 2007;  110 3561-3563
    Search in Google Scholar
  • 18 Sanchorawala V, Wright D G, Rosenzweig M, Finn K T, Fennessey S, Zeldis J B, Skinner M, Seldin D C. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.  Blood. 2007;  109 492-496
    Search in Google Scholar
  • 19 Westermark P, Benson M D, Buxbaum J N, Cohen A S, Frangione B, Ikeda S, Masters C L, Merlini G, Saraiva M J, Sipe J D. A primer of amyloid nomenclature.  Amyloid. 2007;  14 179-183
    Search in Google Scholar

Dr. Stefan Schönland

Universitätsklinikum Heidelberg, Medizinische Klinik V

Im Neuenheimer Feld 410

69120 Heidelberg

Phone: 06221/56 8001

Fax: 06221/56 4659

Email: stefan.schoenland@med.uni-heidelberg.de